Rakkohauru Super Serum Clinical Study Under Dermatological Control

Rakkohauru Super Serum has been clinically tested under dermatological control.
The study confirmed significant wrinkle reduction, improved skin elasticity and firmness, smaller pores, reduced pigmentation, and alleviation of redness and itching in eczema-prone skin. In addition, the serum was shown to strengthen the skin barrier.

Clinical Study: Rakkohauru Super Serum Efficacy on Wrinkles, Pores, Eczema, Redness, Itching, Elasticity, and the Skin Barrier

–29.9% fewer wrinkles

–18.8% less skin laxity

+14.3% more elasticity and firmness

–37.12% smaller pores

–39.56% less pigmentation

–53.30% less redness

–73.86% less itching

–20.7% reduced trans-epidermal water loss (TEWL)

How Rakkohauru Super Serum Stands Out

In clinical tests, Rakkohauru Super Serum delivered exceptionally comprehensive results: reducing wrinkles, strengthening elasticity and firmness, lowering skin moisture loss, and addressing seven different skin concerns, including pores, pigmentation, redness, and itching.

–29.9% fewer wrinkles

–18.8% less skin laxity

+14.3% more elasticity and firmness

–37.12% smaller pores

–39.56% less pigmentation

–53.30% less redness

–73.86% less itching

–20.7% reduced TEWL

Why 20 Participants is a Valid Standard

In clinical cosmetics research, 20 participants is an accepted industry standard to support strong clinical claims when results are statistically significant.

The EU Cosmetics Regulation (EC No 1223/2009) and the Claims Regulation (EU No 655/2013) require that all cosmetic marketing claims are supported by adequate and verifiable evidence. The Commission’s Technical Document (2017) specifies that studies must be reliable, reproducible, and statistically significant, but it does not set a minimum participant number.

Independent research institutes, such as Eurofins, typically conduct “in use” clinical studies with 20 volunteers. This number has become industry standard, as it reliably produces statistically significant results on outcomes such as wrinkle reduction, improved elasticity, or reduced redness.

What matters most is that the study is conducted according to an approved protocol, supervised by an ethics committee, and analyzed with proper statistical methods.

IN USE TEST UNDER DERMATOLOGICAL CONTROL AND INSTRUMENTAL EVALUATIONS

The clinical study was carried out with 28 days of twice-daily use. Final assessments were performed after approximately four weeks, with the protocol allowing a margin of ±2 days.

Study Objectives and Results

Wrinkle Reduction:

Statistically significant reduction in wrinkles around crow’s feet, forehead, and under-eye area after 28 days (clinical grading).

Visioline® VL 650 skin topography analysis confirmed reduced wrinkle area, length, depth, and number after 29 days.

Pore Size:

Statistically significant pore size reduction after 29 days.

Eczema Symptoms and Discomfort (Redness, Itching, Pigmentation):

Redness (erythema) reduced significantly after 29 days (clinical evaluation and Mexameter® MX18).

Pigmentation decreased significantly after 28 days.

Itching improved significantly according to self-assessments after 28 days.

DLQI (Dermatology Life Quality Index) showed a significant improvement in participants’ perceived well-being after 28 days.

Elasticity and Firmness:

Cutometer® MPA 580 instrumental measurements confirmed significant improvements after 29 days.

Reduced skin deformation (Uf, Ue) and increased elastic recovery (Ur/Ue, Ur/Uf) demonstrated stronger elasticity and firmness.

Skin Barrier:

Tewameter® TM 300 showed significantly reduced TEWL after 29 days, indicating a stronger barrier and improved moisture retention.

Summary and Conclusions

Under study conditions, Saaren Taika Rakkohauru Super Serum demonstrated:

Significant reduction in wrinkles (clinical and instrumental).

Significant reduction in pore size.

Significant reduction in redness, itching, and pigmentation.

Significant improvement in elasticity and firmness.

Significant strengthening of the skin barrier (TEWL).

Significant improvement in participant well-being (DLQI).

Consumer Evaluation

After 28 days of use:

100% of participants reported their skin felt hydrated, nourished, soft, silky, and smooth.

Skin looked younger, fresher, and firmer.

Pore size was reduced.

Redness decreased, itching subsided, and skin texture improved.

Participants were satisfied with the efficacy, willing to purchase and reuse the product, and would recommend it to a friend.

Over 95% reported visibly reduced wrinkles and fine lines.

Study Design

20 participants, aged 40–70, with normal to dry, eczema-prone skin and erythema.

Serum applied twice daily for 28 ±2 days, focusing on crow’s feet, forehead, and under-eye area before moisturizer.

Neutral moisturizer allowed if needed.

Conducted under dermatological control with continuous monitoring of tolerance (well tolerated).

Independent study by EUROFINS, completed in 2025.

Methods Used:

Clinical grading of wrinkles, pores, and eczema symptoms.

Instrumental measurements:

Visioline® VL 650 (wrinkles)

Mexameter® MX18 (redness)

Cutometer® MPA 580 (elasticity, firmness)

Tewameter® TM 300 (TEWL, skin barrier)

Self-assessments: itching severity + DLQI questionnaire.

Consumer vs. Clinical Studies

Consumer studies reflect user experience but may be biased toward positive feedback.

Dermatological and clinical studies are independent, supervised by physicians, and follow strict scientific protocols. They assess safety and efficacy objectively, reporting both positive and negative outcomes.